Type 1 Diabetes Clinical Trial
— VIGOROfficial title:
The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial
NCT number | NCT01834144 |
Other study ID # | B2012:136 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | May 2013 |
Est. completion date | June 15, 2015 |
Verified date | January 2018 |
Source | University of Manitoba |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background/Justification: Regular physical activity (PA) has substantial health benefits in
persons with type 1 diabetes (T1D), including reduced risk of complications and
cardiovascular mortality. Despite these benefits, individuals with T1D remain significantly
less active than their peers without diabetes. Two major factors likely explain the low rates
of PA in young people with T1D: (1) fear of post-exercise hypoglycaemia, particularly
nocturnal hypoglycaemia, and (2) a lack of empirical evidence for the efficacy of PA for
achieving optimal glycaemic control. A number of acute exercise trials recently demonstrated
that the inclusion of vigorous intensity PA in conventional moderate intensity (i.e. walking)
PA sessions may overcome these limitations. No studies have tested the efficacy of high
intensity PA for reducing the risk of exercise-related hypoglycaemia or glycaemic variability
in a randomized controlled trial (RCT).
Study Hypotheses: In persons 15-35 years of age living with T1D, this study will test the
hypotheses that (1) the addition of intermittent vigorous intensity PA to a moderate
intensity intervention will reduce the time spent in hypoglycaemia in the 12 hour period
following exercise and (2) the addition of intermittent vigorous intensity PA to a moderate
intensity PA intervention will elicit significant improvements in glycemic excursions, as
measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour period
following exercise.We are also exploring the hypothesis that reducing the risk of
hypoglycemia will lead to a sustained increase in physical activity one year after
randomization.
Status | Terminated |
Enrollment | 4 |
Est. completion date | June 15, 2015 |
Est. primary completion date | June 15, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Age: 15-45 years old - Have lived with type 1 diabetes for at least 2 years - HbA1c <9.9% - Currently physically inactive (<150 minutes of self-reported structured physical activity per week) - Undergone a resting ECG to screen for left ventricular hypertrophy, arrhythmias or signs or coronary artery disease that may be exacerbated with vigorous intensity exercise Exclusion Criteria: - Have frequent and unpredictable hypoglycaemia - Had a change in insulin management strategy, including adoption of a pump, within 2 months of enrolment - Are currently participating in structured activity or sport-related activities - Are women who are pregnant or planning to get pregnant within the 12 months of the trial and those who are breastfeeding - Have conditions that would render physical activity contraindicated including: uncontrolled hypertension (BP>150mmHg systolic or >95mmHg diastolic in a sitting position); severe peripheral neuropathy; history of cardiovascular disease - Have a cognitive deficit resulting in an inability to provide informed consent - Currently taking beta blockers - Currently taking atypical antipsychotics or corticosteroids |
Country | Name | City | State |
---|---|---|---|
Canada | University of Calgary | Calgary | Alberta |
Canada | University of Alberta | Edmonton | Alberta |
Canada | McMaster University | Hamilton | Ontario |
Canada | University of Ottawa | Ottawa | Ontario |
Canada | Manitoba Institute of Child Health | WInnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
University of Manitoba | Manitoba Institute of Child Health |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time Spent in Hypoglycaemia in the 12-hour Period Following Exercise, Defined as an Interstitial Glucose Reading <4.0mmol/L and Measured by Continuous Glucose Monitor. | Measured at baseline, and 1, 8,16 and 52 weeks following randomization | ||
Secondary | Glycaemic Variability, Measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour Period Following Exercise. This is Calculated From the Same Continuous Glucose Monitor Data as the Primary Outcome. | Measured at baseline, and 1, 8, 16 and 52 weeks following randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 | |
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A |